By contrast, in older/unfit patients with newly diagnosed, FLT3-mutated AML treated with HMA plus venetoclax, the ORR was 70% with a median OS of 15 months in subgroup analysis [30]. Here, FLT3 is linked to acute myeloid leukemia.